RxDoctor Payments Data

Leslie Bank, MD

Gastroenterology · Binghamton, NYNPI 1124000310

Payments from drug & device makers

$69,256in general payments, 2019–2025

Across 182 payments — averaging $380.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$57K
  • Janssen Research & Development, LLC$11K
  • Johnson & Johnson$454
  • Takeda Pharmaceuticals U.S.A., Inc.$271
  • Pfizer$219
  • Gilead$212
  • plus $926 from 21 others

What the payments were for

  • Consulting fees$160%
  • Food & beverage$3,28999%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,256 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$52,392
Medicare patients
296
Services billed
567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab13$82,980
Mesalamine30$26,312
Balsalazide Disodium19$4,294
Entecavir16$3,259
Pantoprazole Sodium154$2,346
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates29$1,890
Tacrolimus12$1,719
Mercaptopurine11$1,335
Esomeprazole Magnesium14$991
Sucralfate17$973
Dicyclomine Hcl29$469
Omeprazole55$430
Famotidine25$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira$56,673$82,98013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →